Other than launching new trials I don't think much else is going to happen this year.
At least it's nice to see they're considering synthetic bryo for the next trial. No need for bioequivalence trials if they drop the natural version and go straight for synthetic version approval. Dropping the severe patients and only focusing on moderate ones should also provide better results for the next trial. Hopefully they'll also find a way to prevent another baseline imbalance.
Cue another year of arguing and debating before they cause another ruckus with new results. Third time's the charm, right?
News 
Market Data 
Discover 
AI
